With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled ...

Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

Sanofi said its Opella business has been valued at around 16 billion euros (USD17.38 billion), or 14 times EBITDA in 2024 ...

The FDA has cleared the start of clinical trial testing of KT-621, an experimental oral medication for COPD and other ...

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the ...

To learn more, go to DUPIXENT.com ((SL Advertiser)) New treatment option for those with chronic obstructive pulmonary disease or COPD. 1 weather alerts 1 closings/delays ...

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...